Gilead Sciences welcomes Kelly Kramer to the Board of Directors and its Audit Committee

– USA, CA –  Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Kelly A. Kramer has been appointed to the company’s Board of Directors and Audit Committee.

“We are very pleased to welcome Kelly Kramer to the Board of Directors of Gilead Sciences,” said John Martin, PhD, Executive Chairman. “Kelly’s deep financial expertise in the technology and healthcare industries, including mergers and acquisitions, will be valuable as Gilead continues to grow across multiple therapeutic areas and around the world. I look forward to the contributions and insights that she will bring to the Board.”

About Kelly Kramer

Ms. Kramer is currently Executive Vice President and CFO Cisco Systems, Inc., which designs and sells products, services and solutions to securely connect everyone and everything. She previously served for 20 years in senior finance positions at General Electric, including as CFO GE Healthcare’s Healthcare Systems Business. She is a member of the board of the Silicon Valley Chapter of City Year, a non-profit organization that provides educational support for at-risk students in poor communities.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here the original post =>